Figure 1 from Real-World Outcomes of Elacestrant in ER+, HER2−, ESR1-Mutant Metastatic Breast Cancer

mTTNT benefit in clinical subgroups: (A) 1–2 prior lines of ET ± CDK4/6i, (B) 1–2 prior lines of ET ± CDK4/6i ≥ 12 months, (C) 1 prior line of ET ± CDK4/6i, (D) 2 prior lines of ET ± CDK4/6i, (E) ≥3 prior lines of ET ± CDK4/6i, (F) visceral metastasis, (G) coexisting ESR1 and PI3K pathway mutations, (H) no prior fulvestrant, and (I) no prior chemotherapy.